

Recent evidence from 2024–2025 marks a shift from standardized "bundle" compliance toward individualized, phenotype-driven care. The **European Society of Intensive Care Medicine (ESICM) 2025** guidelines now suggest a ceiling of **up to 30 mL/kg** of crystalloids rather than the traditional "at least 30 mL/kg" minimum, prioritizing frequent reassessment to prevent fluid overload. Early initiation of vasopressors via **peripheral access** is now supported by the **CLOVERS trial ** as safe and effective, provided it occurs within 1–3 hours of shock recognition. **Corticosteroids** are increasingly recommended for all septic shock patients regardless of vasopressor dose (2024/2025 meta-analyses), while **Vitamin C** has been largely abandoned as a standard adjunctive therapy following the neutral results of the **C-EASIE trial **.

1. Hemodynamic Resuscitation: From Minimums to Individualization

The paradigm of fluid resuscitation has shifted from fixed volumes to a more cautious, "dose-response" approach.

- **Fluid Volume (ESICM 2025 / NICE 2025):**The **ESICM 2025 Clinical Practice Guideline**(Part 2) suggests administering **up to 30 mL/kg** of intravenous crystalloids in the initial phase (first 3 hours) but emphasizes that this is a maximum suggestion rather than a mandate. The **NICE 2025 (NG51)** update specifically recommends smaller initial boluses (e.g., 250–500 mL) followed by immediate reassessment for patients at high risk of death, focusing on "carefully calibrated" fluid treatment.
- **Early Vasopressor Timing:** Systematic reviews in **2025 (Annals of Intensive Care)**indicate that initiating vasopressors within 1–3 hours of septic shock diagnosis reduces short-term mortality. However, "extremely early" initiation (within 1 hour) may be harmful if it leads to the omission of necessary fluid resuscitation.
- **Peripheral Administration (CLOVERS 2025):**A secondary analysis of the **CLOVERS trial ** involving 60 US hospitals confirmed that peripheral vasopressor administration is associated with very low complication rates (0.6%) and no mortality difference compared to central access. This supports starting norepinephrine peripherally to avoid delays in stabilizing mean arterial pressure (MAP).

2. Antibiotic Stewardship and Precision Dosing

The focus has moved from "hit fast" to "hit smart and focus."

- **Timing vs. Certainty:** The **2025 S3 (German Sepsis Society)** guidelines maintain the 1-hour window for suspected septic shock but allow up to 3 hours for stable patients when the diagnosis is uncertain, to allow for rapid assessment of non-infectious mimics.
- **Precision Dosing:** The **AutoKinetics trial ** explored model-informed precision dosing (MIPD) for antibiotics. While MIPD significantly improved pharmacokinetic target attainment (69% vs. 48%), it did not significantly reduce mortality and was found to be not cost-effective for universal implementation.
- **AI-Driven Adjustments:** Ongoing studies such as **KI.SEP (2024/2025)** are developing machine learning algorithms to predict antibiotic serum concentrations daily, aiming to replace standard dosing with automated, patient-specific recommendations.

3. Adjunctive Therapies: Steroids and Vitamin C

Recent high-quality meta-analyses have clarified the role of common adjuncts.[2]

- **Corticosteroids (2024-2025 Updates):** New systematic reviews in **2024 (Corticosteroids in Sepsis)** and **Cochrane 2025** provide moderate-certainty evidence that corticosteroids reduce 28-day and hospital mortality (Absolute Risk Reduction ~2%).
- **Indication:** Guidelines now suggest corticosteroids for all patients in septic shock, removing the 2021 Surviving Sepsis Campaign (SSC) threshold of requiring ≥0.25 mcg/kg/min of norepinephrine.
- **Dosing:** Optimal mortality benefit is associated with a total daily hydrocortisone-equivalent dose of **260 mg/day**.[1]
- **Vitamin C (C-EASIE 2025):** The **C-EASIE multicenter RCT ** found that early administration of Vitamin C (within 6 hours) did not reduce organ dysfunction or mortality. Recent systematic reviews (2020–2025) conclude that while it may transiently improve

SOFA scores, there is no consistent mortality benefit, and it is no longer recommended for routine use.

4. Post-Sepsis Care and Subphenotypes

- **Sepsis Subphenotypes:** Research in **2025 (Intensive Care Medicine)** highlights at least four distinct clinical subphenotypes (e.g., α, β, γ, δ) based on temperature, organ dysfunction, and inflammatory markers. The "hypothermic" subphenotype is associated with the highest mortality (32%) and may require different immune-modulating strategies than the "hyperthermic" resolvers.[3]
- **Long-term Follow-up (S3 2025):** The updated **S3 2025** guidelines introduced a major new focus on structured follow-up care. They recommend dedicated post-ICU clinics and screening for "Post-Sepsis Syndrome," which includes persistent cognitive impairment and physical disability, recognizing these as core components of sepsis management rather than separate recovery issues.[4][5]

INTERVENTION	2021 SSC STATUS	2024–2025 STATUS UPDATE
Initial Fluids	At least 30 mL/kg	Up to 30 mL/kg; reassess after small boluses
Vasopressor Route	Prefer Central	Peripheral is safe and reduces delay
Corticosteroids	Only if high-dose vasopressors	Recommended for all septic shock
Vitamin C	Weakly against	Strong evidence against routine use
Antibiotics	Standardized 1h bundle	Personalized dosing; 3h window for low-risk

References (5)

[1]
[Update 2025 of the S3 guidelines: "Sepsis-Prevention, diagnosis, treatment and follow-up care" : What is new?].
Neumann C; Ebert D; Bucher M; Bauer M
Die Anaesthesiologie
2025-12
Q3H-index: 48

[2]
Corticosteroids in Sepsis and Septic Shock: A Systematic Review, Pairwise, and Dose-Response Meta-Analysis
Tyler Pitre; Katherine Drover; Dipayan Chaudhuri; Dena Zeraaktkar; Kusum Menon; Hayley B. Gershengorn; Namita Jayaprakash; Joanna L. Spencer-Segal; Stephen M. Pastores; Andrea M. Nei; Djillali Annane; Bram Rochwerg
Critical Care Explorations
2024
Q1H-index: 22925 citations

[3]
Intravenous Vitamin C in Severe Sepsis: A Systematic Review of Evidence From 2020 to 2025

Rana Ahmed; Shashwat Shetty; Muhammad Qaiser Aziz Khan; Iqra Kalsoom; Shazia Qasim; Shair Bahadar Khan; Saad Abdullah
Cureus
Q1H-index: 9
[4]

Continuous vs. intermittent infusion of corticosteroids in septic shock: a GRADE-based systematic review and meta-analysis

Parinaz Sadat Mahmoudi; Farhood Sadeghi; Mehran Saberian; Hossein Khalili; Maryam Shafaati

Journal of Anesthesia, Analgesia and Critical Care

2026

Q1H-index: 229
[5]

Aiming for precision: personalized medicine through sepsis subtyping

Aryna Kolodyazhna; W Joost Wiersinga; Tom van der Poll

Burns & Trauma

2025

Q1H-index: 465 citations